Related Experiment Video

Updated: Jun 2, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

MRP8/14 is associated with systemic inflammation in stable coronary atherosclerosis in men

Marcus Baumann1, Christoph Schmaderer, Klaus Burkhardt

  • 1Department of Nephrology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany. marcus.baumann@lrz.tum.de

European Journal of Clinical Investigation
|May 6, 2011
PubMed
Abstract

Insights

Circulating MRP8/14 levels correlate with inflammation markers in male patients with coronary artery disease (CAD). However, this study found no link between MRP8/14 and the severity of stable CAD.

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Biochemistry

Background:

  • MRP8/14, a phagocyte activation marker, is implicated in atherogenesis and vascular injury.
  • Elevated MRP8/14 levels are associated with acute cardiovascular events.
  • Phagocyte activation plays a key role in atherosclerotic processes.

Purpose of the Study:

  • To investigate the correlation between circulating MRP8/14 levels and chronic coronary artery disease (CAD) stages.
  • To assess the relationship between MRP8/14 and atherosclerotic burden.
  • To determine if MRP8/14 levels differ between CAD patients and controls.

Main Methods:

  • Observational, cross-sectional study involving 240 male subjects undergoing coronary angiography.
  • Quantification of serum MRP8/14 levels using ELISA.
  • Assessment of atherosclerotic burden using Severity, Gensini, and Extent Scores.

Main Results:

  • Serum MRP8/14 levels were significantly associated with hs-CRP, IL-6, and fibrinogen (P < 0.001).
  • No association was found between MRP8/14 and other cardiovascular disease risk factors.
  • MRP8/14 levels did not differ between stable CAD patients and control subjects (P = 0.69).
  • No correlation was observed between circulating MRP8/14 and atherosclerotic wall irregularities.

Conclusions:

  • MRP8/14 is significantly associated with systemic inflammation markers in male CAD patients.
  • Circulating MRP8/14 complex does not correlate with the severity of stable coronary artery disease.

More Related Videos

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

Related Concept Videos

Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Mitral Regurgitation II: Clinical Features and Diagnostic Tests01:23

Mitral Regurgitation II: Clinical Features and Diagnostic Tests

Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...